Published in PLoS One on August 16, 2010
Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol (2012) 1.11
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One (2011) 1.07
Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One (2011) 1.05
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses (2014) 1.04
MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One (2014) 0.93
Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin. J Virol (2015) 0.83
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccines (Basel) (2015) 0.81
Mimotopes selected with neutralizing antibodies against multiple subtypes of influenza A. Virol J (2011) 0.79
Viral vector-based influenza vaccines. Hum Vaccin Immunother (2016) 0.79
Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response. PLoS One (2016) 0.76
Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins. Open Forum Infect Dis (2016) 0.75
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. J Virol (2017) 0.75
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol (1968) 5.69
The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology (1998) 4.13
Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A (2000) 3.95
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol (1991) 3.83
The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology (1998) 3.35
Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci U S A (1987) 2.84
Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J Immunol (1992) 2.60
CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev (2006) 2.49
Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol (2005) 2.13
Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol (1998) 2.03
Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J Immunol (1999) 1.99
From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol (2004) 1.98
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine (1996) 1.86
The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol (2000) 1.65
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine (2009) 1.51
Pandemic influenza as a current threat. Curr Top Microbiol Immunol (2009) 1.49
A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses (2009) 1.42
The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand J Immunol (1978) 1.36
Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J Immunol (2009) 1.35
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine (2007) 1.35
Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. Virology (1994) 1.28
Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol (2000) 1.22
Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis (2007) 1.18
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One (2010) 1.15
Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis (2009) 1.13
Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol (2002) 1.11
The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology (2009) 1.01
Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine (2009) 0.99
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J Immunol (2009) 0.99
MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One (2009) 0.95
Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol (2009) 0.94
Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Arch Virol (1998) 0.94
Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees. Infect Immun (1984) 0.94
Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Virology (1998) 0.93
Analysis of the restriction to the growth of nonegg-adapted human influenza virus in eggs. Virology (1993) 0.91
Learning from our foes: a novel vaccine concept for influenza virus. Arch Virol Suppl (1999) 0.79
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis (2013) 3.46
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med (2008) 3.28
Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (2011) 2.49
Inactivation of hepatitis A variants during heat treatment (pasteurization) of human serum albumin. Transfusion (2011) 2.00
Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori. Infect Immun (2002) 1.70
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis (2013) 1.64
Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations. Transplantation (2011) 1.48
[Vaccine protection in the elderly: are Austrian seniors adequately protected by vaccinations?]. Wien Klin Wochenschr (2002) 1.46
Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines (2009) 1.38
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine (2007) 1.35
A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine (2005) 1.34
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One (2010) 1.15
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis (2011) 1.13
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis (2009) 1.10
Tick-borne encephalitis virus vaccine as additional alternative neoantigen for the clinical immunologist's toolbox. J Allergy Clin Immunol (2012) 1.08
Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine (2009) 1.08
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One (2011) 1.07
Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. Transfusion (2012) 1.06
A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis (2011) 1.06
Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J (2009) 1.05
West Nile virus infection in plasma of blood and plasma donors, United States. Emerg Infect Dis (2009) 1.04
Quantitative detection of Borrelia burgdorferi sensu lato in erythema migrans skin lesions using internally controlled duplex real time PCR. PLoS One (2013) 1.02
Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther (2003) 0.99
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion (2009) 0.97
A new approach to a Lyme disease vaccine. Clin Infect Dis (2011) 0.96
Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. Vaccine (2009) 0.95
Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol (2009) 0.94
Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion (2007) 0.94
Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine (2011) 0.93
West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis (2007) 0.92
Hepatitis A virus antibodies in immunoglobulin preparations. J Allergy Clin Immunol (2009) 0.91
Clinical, neuropathological and immunohistochemical features of sporadic and variant forms of Creutzfeldt-Jakob disease in the squirrel monkey (Saimiri sciureus). J Gen Virol (2007) 0.91
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine (2011) 0.90
Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF. J Biol Chem (2012) 0.90
Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus. J Virol (2010) 0.90
Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes. Vaccine (2011) 0.90
Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine (2010) 0.89
Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza. Transfusion (2011) 0.89
Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations. Clin Vaccine Immunol (2012) 0.89
Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem (2008) 0.87
Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine (2011) 0.87